retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide is a triple-agonist (GLP-1
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18




























